NEW YORK (GenomeWeb) — Veracyte reported after the close of the market on Wednesday that fourth quarter revenues rose 30 percent year over year, driven by strong growth in demand for the company's Afirma gene expression classifier (GEC) test, which is used in thyroid cancer diagnosis.

For the three-month period ended Dec. 31, Veracyte's revenues grew to $18.3 million from $14.0 million in Q4 2015, surpassing the analyst consensus estimate of $17.5 million.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

A new analysis examines the gender gap among paper authors in the sciences and says it may take decades or more to close.

Researchers have uncovered signals of selection that may enable the Bajau people to free five hundreds of feet deep, Reuters reports.

In Science this week: paternally inherited cis-regulatory structural variants in autism, and more.

A new report outlines issues facing the implementation of personalized medicine in the UK, the Independent reports.